Chronic kidney disease (CKD) presents a significant challenge to healthcare systems in Australia and internationally. The National Kidney Foundation (NKF) (NKF) (2020) reported 26 million people worldwide are diagnosed with moderate to severe CKD. In the Australian population, there are an estimated 1.7 million people diagnosed with moderate to severe CKD and a further 1.5 million Australians unaware and undiagnosed with the disease (Australian Institute of Health and Welfare, 2023). The prevalence of CKD has likely increased over the last few years due to the growing number of people with cardiovascular disease, diabetesand the increasing age of the population (Australian Institute of Health and Welfare, 2023). The challenge for health care professionals is that CKD is largely a silent disease whereby 90 % of kidney function can be lost before symptoms manifest.

The insidious nature of CKD demands a clinical imperative for early identification, with the priority of minimising disease progression and its associated cardiovascular risk. The progression of CKD can be reduced by 20–50 % if it is detected early and evidence-based management is implemented (Johnson et al., 2013). Screening practices consist of identifying people at risk of CKD and initiating a kidney health check which involves a urine test for albumin-creatinine ratio (ACR), a blood test to determine an estimated glomerular filtration rate (eGFR) and measuring blood pressure for the detection of hypertension.